The UK will be the first country to run final-stage trials of a coronavirus vaccine being developed by a company owned by Johnson and Johnson.

The phase-three trial of the vaccine from pharmaceutical company Janssen starts on Monday and will be the first of its two-dose study.

The jab has already undergone phase one and two trials, and interim analysis of the single-dose study suggests the Covid-19 vaccine candidate induces a robust immune response and is generally well-tolerated.

For the two-dose study, researchers are aiming to recruit around 6,000 UK participants – from a total of 30,000 people globally – at 17 sites across the country.

These include Southampton, Bristol, Cardiff, London, Leicester, Sheffield, Manchester, Dundee and Belfast.

Recruitment into the study will complete in March 2021 and the trial will last for 12 months.

The Janssen vaccine will be the third to be trialled in the UK, along with the Oxford/AstraZeneca candidate, and one from US biotech company Novavax.

So far around 25,000 people in the UK have participated in vaccine trials, and more than 310,000 have indicated their willingness to take part in clinical studies by signing up to the NHS vaccine research registry.

Saul Faust, professor of paediatric immunology and infectious diseases at the University of Southampton and University Hospital Southampton NHS Foundation Trust, said: “We just don’t know how each of these vaccines is going to behave and which are going to generate the better short and long-term immunity.

“And we can’t be certain that vaccine supply will be efficient and effective and secure from any one manufacturer, wherever it’s being made in the world.”

Kate Bingham, chairwoman of the UK’s Vaccine Taskforce, said: “Because we’ve got this national citizen registry of volunteers willing to go into clinical trials, it has accelerated our ability to enrol trials.

“And that means that the UK is a very favourable place to come in and run studies and so Novavax has expanded that study, and of course Janssen has come to the UK for the first, I think, of its two-dose study.”

The UK has secured 30 million doses of the Janssen vaccine if the trial is successful.

Prof Faust, who is principal investigator of the Janssen trial in the UK, said there are 40,000 people on the NHS vaccine registry who are in the postcode areas around the vaccine centres for the Janssen study.

They are expected to be contacted in the second half of this week and invited to take part in the study.

The vaccine candidate Janssen is trialling is an adenoviral vaccine, like the one Oxford University is working on.

These are based on weakened versions of adenoviruses, which are a group of viruses that typically infect membranes of the eyes, respiratory tract, urinary tract, intestines and nervous system, and include the common cold.

Last week US firm Pfizer announced its vaccine has been found to be more than 90% effective in preventing Covid-19. It is not an adenoviral vaccine and needs to be held at minus 70C, so is less easy to deploy. 

Adam Finn, professor of paediatrics at University of Bristol, said the adenovirus vector does not prevent anyone from being suitable for the vaccination.

“For example, if you were immuno-deficient or something, there’s no reason to imagine that’s going to be a risk to you,” he said.

The UK researchers say the timing of results for their study will depend on global recruitment to the trial and the incidence of Covid-19.

They add that recent vaccine trials suggest it generally takes six to nine months to get an outcome, but it could be longer for trials starting out now.

Prof Faust said: “It is going to be some time before the bulk of the population receive a coronavirus vaccine just because of the technical difficulties of manufacturing, achieving the number of vaccines in the UK, and then deployment in that many people.”

The researchers also stress that participating in a vaccine trial would not exclude anyone from routine immunisation later.